1. Home
  2. GANX vs JRSH Comparison

GANX vs JRSH Comparison

Compare GANX & JRSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • JRSH
  • Stock Information
  • Founded
  • GANX 2017
  • JRSH 2016
  • Country
  • GANX United States
  • JRSH United States
  • Employees
  • GANX N/A
  • JRSH N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • JRSH Apparel
  • Sector
  • GANX Health Care
  • JRSH Consumer Discretionary
  • Exchange
  • GANX Nasdaq
  • JRSH Nasdaq
  • Market Cap
  • GANX 41.9M
  • JRSH 36.5M
  • IPO Year
  • GANX 2021
  • JRSH 2018
  • Fundamental
  • Price
  • GANX $1.85
  • JRSH $3.30
  • Analyst Decision
  • GANX Strong Buy
  • JRSH
  • Analyst Count
  • GANX 4
  • JRSH 0
  • Target Price
  • GANX $7.75
  • JRSH N/A
  • AVG Volume (30 Days)
  • GANX 281.8K
  • JRSH 13.9K
  • Earning Date
  • GANX 11-14-2024
  • JRSH 11-12-2024
  • Dividend Yield
  • GANX N/A
  • JRSH 6.06%
  • EPS Growth
  • GANX N/A
  • JRSH N/A
  • EPS
  • GANX N/A
  • JRSH N/A
  • Revenue
  • GANX N/A
  • JRSH $130,270,418.00
  • Revenue This Year
  • GANX N/A
  • JRSH $23.86
  • Revenue Next Year
  • GANX $300.03
  • JRSH $10.89
  • P/E Ratio
  • GANX N/A
  • JRSH N/A
  • Revenue Growth
  • GANX N/A
  • JRSH N/A
  • 52 Week Low
  • GANX $0.89
  • JRSH $2.68
  • 52 Week High
  • GANX $5.33
  • JRSH $3.46
  • Technical
  • Relative Strength Index (RSI)
  • GANX 39.86
  • JRSH 71.44
  • Support Level
  • GANX $1.64
  • JRSH $2.93
  • Resistance Level
  • GANX $2.34
  • JRSH $3.46
  • Average True Range (ATR)
  • GANX 0.27
  • JRSH 0.12
  • MACD
  • GANX -0.09
  • JRSH 0.03
  • Stochastic Oscillator
  • GANX 19.90
  • JRSH 71.05

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

About JRSH Jerash Holdings (US) Inc.

Jerash Holdings (US) Inc along with its subsidiaries is a manufacturer and exporter of customized, ready-made sport and outerwear from knitted fabric from its production facilities in Jordan. The company manufactures for retailers namely Walmart, Costco, Sears, Hanes, Columbia, Land's End, VF Corporation, and Philip-Van Heusen which owns brands such as The North Face, Nautica, Timberland, Wrangler, Lee, Jansport, Calvin Klein, Tommy Hilfiger, IZOD, Speedo etc. It derives its revenue from the manufacturing and sales of outerwear in the United States. The company's product offering consists of jackets, polo shirts, crew neck shirts, pants, and shorts made from knitted fabric. Geographically, the company generates maximum revenue from the United States.

Share on Social Networks: